Tags

Type your tag names separated by a space and hit enter

Progress on norovirus vaccine research: public health considerations and future directions.
Expert Rev Vaccines. 2018 09; 17(9):773-784.ER

Abstract

INTRODUCTION

Noroviruses are the leading cause of foodborne illness worldwide, account for approximately one-fifth of acute gastroenteritis (AGE) cases globally, and cause a substantial economic burden. Candidate norovirus vaccines are in development, but there is currently no licensed vaccine.

AREAS COVERED

Noroviruses cause approximately 684 million cases and 212,000 deaths per year across all age groups, though burden estimates vary by study and region. Challenges to vaccine research include substantial and rapidly evolving genetic diversity, short-term and homotypic immunity to infection, and the absence of a single, well-established correlate of protection. Nonetheless, several norovirus vaccine candidates are currently in development, utilizing virus-like particles (VLPs), P particles, and recombinant adenoviruses. Of these, a bivalent GI.1/GII.4 VLP-based intramuscular vaccine (Phase IIb) and GI.1 oral vaccine (Phase I) are in clinical trials.

EXPERT COMMENTARY

A norovirus vaccine should target high-risk populations, including the young and the elderly, and protect them against the most common circulating norovirus strains. A norovirus vaccine would be a powerful tool in the prevention and control of norovirus while lessening the burden of AGE worldwide. However, more robust burden and cost estimates are needed to justify investments in and guide norovirus vaccine development.

Authors+Show Affiliations

a Oak Ridge Institute for Science and Education , Oak Ridge , TN , USA. b Division of Viral Diseases, Viral Gastroenteritis Branch , Centers for Disease Control and Prevention , Atlanta , USA.b Division of Viral Diseases, Viral Gastroenteritis Branch , Centers for Disease Control and Prevention , Atlanta , USA.b Division of Viral Diseases, Viral Gastroenteritis Branch , Centers for Disease Control and Prevention , Atlanta , USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

30092671

Citation

Mattison, Claire P., et al. "Progress On Norovirus Vaccine Research: Public Health Considerations and Future Directions." Expert Review of Vaccines, vol. 17, no. 9, 2018, pp. 773-784.
Mattison CP, Cardemil CV, Hall AJ. Progress on norovirus vaccine research: public health considerations and future directions. Expert Rev Vaccines. 2018;17(9):773-784.
Mattison, C. P., Cardemil, C. V., & Hall, A. J. (2018). Progress on norovirus vaccine research: public health considerations and future directions. Expert Review of Vaccines, 17(9), 773-784. https://doi.org/10.1080/14760584.2018.1510327
Mattison CP, Cardemil CV, Hall AJ. Progress On Norovirus Vaccine Research: Public Health Considerations and Future Directions. Expert Rev Vaccines. 2018;17(9):773-784. PubMed PMID: 30092671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progress on norovirus vaccine research: public health considerations and future directions. AU - Mattison,Claire P, AU - Cardemil,Cristina V, AU - Hall,Aron J, Y1 - 2018/08/27/ PY - 2018/8/11/pubmed PY - 2019/2/7/medline PY - 2018/8/11/entrez KW - Norovirus KW - acute gastroenteritis KW - burden of disease KW - vaccine development KW - virus-like particles SP - 773 EP - 784 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 17 IS - 9 N2 - INTRODUCTION: Noroviruses are the leading cause of foodborne illness worldwide, account for approximately one-fifth of acute gastroenteritis (AGE) cases globally, and cause a substantial economic burden. Candidate norovirus vaccines are in development, but there is currently no licensed vaccine. AREAS COVERED: Noroviruses cause approximately 684 million cases and 212,000 deaths per year across all age groups, though burden estimates vary by study and region. Challenges to vaccine research include substantial and rapidly evolving genetic diversity, short-term and homotypic immunity to infection, and the absence of a single, well-established correlate of protection. Nonetheless, several norovirus vaccine candidates are currently in development, utilizing virus-like particles (VLPs), P particles, and recombinant adenoviruses. Of these, a bivalent GI.1/GII.4 VLP-based intramuscular vaccine (Phase IIb) and GI.1 oral vaccine (Phase I) are in clinical trials. EXPERT COMMENTARY: A norovirus vaccine should target high-risk populations, including the young and the elderly, and protect them against the most common circulating norovirus strains. A norovirus vaccine would be a powerful tool in the prevention and control of norovirus while lessening the burden of AGE worldwide. However, more robust burden and cost estimates are needed to justify investments in and guide norovirus vaccine development. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/30092671/Progress_on_norovirus_vaccine_research:_public_health_considerations_and_future_directions_ L2 - http://www.tandfonline.com/doi/full/10.1080/14760584.2018.1510327 DB - PRIME DP - Unbound Medicine ER -